Skip to content

Rolandic Epilepsy Genomewide Association International Study

Rolandic Epilepsy Genomewide Association International Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03547050
Acronym
REGAIN
Enrollment
210
Registered
2018-06-06
Start date
2018-06-01
Completion date
2023-06-30
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rolandic Epilepsy

Keywords

Epilepsy, Rolandic, Genetics, Genomewide Association Study, RE, Neurology, Pediatrics

Brief summary

We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

Detailed description

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 25% of child patients have Rolandic Epilepsy or RE, also known as Benign Epilepsy with Centrotemporal Spikes (BECTS). RE has a complex genetic basis, probably made up of combinations of susceptibility variants in different genes. Children with RE quite often have other symptoms that affect their speech, attention, reading ability or coordination. The goal of this study is to find the genetic basis for susceptibility to seizures and associated comorbidities for RE using genomewide association approaches. We know that RE has a genetic basis and we recently discovered the genetic cause of the EEG pattern seen in RE. The goal of REGAIN is to now find the genetic basis for susceptibility to seizures and the associated symptoms above. Our hope is to be able to improve diagnosis and understand why each child with RE is different, and perhaps point us towards new treatments that are more effective and have fewer side effects. We will compare the genetic code of 3,000 children with RE against a similar number of people not affected by epilepsy. With the proposed large sample of participants, we will be able to pinpoint the exact changes that might lead to seizures or attention problems for example. Learning the genetic basis for these problems will deepen our understanding of the mechanisms and lead to new treatments or cures.

Interventions

OTHERBlood draw

Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

Control DNA samples will be used that have been previously acquired in other studies.

Sponsors

King's College Hospital NHS Trust
CollaboratorOTHER
Guy's and St Thomas' NHS Foundation Trust
CollaboratorOTHER
Cardiff University
CollaboratorOTHER
The Hospital for Sick Children
CollaboratorOTHER
Hospital JP Garrahan
CollaboratorOTHER_GOV
Aghia Sophia Children's Hospital of Athens
CollaboratorOTHER
Hospital Mutua de Terrassa
CollaboratorOTHER
Seattle Children's Hospital
CollaboratorOTHER
Hasbro Children's Hospital
CollaboratorOTHER
Columbia University
CollaboratorOTHER
King's College London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
6 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of Rolandic Epilepsy in accordance with the following international criteria: * Age of first afebrile seizure 3-12 years * Seizures comprising focal sensorimotor seizures affecting the vocal tract and face, with or without involvement of the arm * Predominant sleep-related seizures * EEG interictal centro-temporal spikes with normal background 2. Current age 6-25 years

Exclusion criteria

1. No history of focal seizure 2. Normal EEG or abnormal background features on EEG 3. Known structural causes (stroke, tuberous sclerosis, infection, post-infectious or metabolic) 4. Primary diagnosis of autism or global learning disability 5. Focal central neurological deficit on clinical exam, 6. Unable to provide informed consent 7. Unable to provide blood sample

Design outcomes

Primary

MeasureTime frameDescription
Allelic association p value corrected for genome wide testingDay 1We will look to see if there are changes in the genetic code that cause brainwave abnormalities close to the genetic changes that we have already discovered.

Countries

Argentina, Canada, Greece, Italy, Spain, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026